Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome

Raksha Jain, Ramsey R. Hachem, Matthew R. Morrell, Elbert P. Trulock, Murali M. Chakinala, Roger D. Yusen, Howard J. Huang, Thalachallour Mohanakumar, G. Alexander Patterson, Michael J. Walter

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background: Previous studies have suggested that azithromycin improves lung function in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). However, these studies did not include a non-treated BOS control cohort or perform survival analysis. This study was undertaken to estimate the effect of azithromycin treatment on survival in lung transplant recipients with BOS. Methods: We conducted a retrospective cohort study of consecutive lung transplant recipients who developed BOS between 1999 and 2007. An association between azithromycin treatment and death was assessed using univariate and multivariate time-dependent Cox regression analysis. Results: Of the 178 recipients who developed BOS in our study, 78 did so after 2003 and were treated with azithromycin. The azithromycin-treated and untreated cohorts had similar baseline characteristics. Univariate analysis demonstrated that azithromycin treatment was associated with a survival advantage and this beneficial treatment effect was more pronounced when treatment was initiated during BOS Stage 1. Multivariate analysis demonstrated azithromycin treatment during BOS Stage 1 (adjusted hazard ratio = 0.23, p = 0.01) and absolute forced expiratory volume in 1 second (FEV1) at the time of BOS Stage 1 (adjusted hazard ratio = 0.52, p = 0.003) were both associated with a decreased risk of death. Conclusions: In lung transplant recipients with BOS Stage 1, azithromycin treatment initiated before BOS Stage 2 was independently associated with a significant reduction in the risk of death. This finding supports the need for a randomized, controlled trial to confirm the impact of azithromycin on survival in lung transplant recipients.

Original languageEnglish (US)
Pages (from-to)531-537
Number of pages7
JournalJournal of Heart and Lung Transplantation
Volume29
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Bronchiolitis Obliterans
Azithromycin
Lung
Survival
Therapeutics
Transplant Recipients
Forced Expiratory Volume
Risk Reduction Behavior
Survival Analysis
Cohort Studies
Multivariate Analysis
Randomized Controlled Trials
Retrospective Studies
Regression Analysis

Keywords

  • azithromycin
  • bronchiolitis
  • chronic rejection
  • lung transplant
  • macrolides
  • survival

ASJC Scopus subject areas

  • Transplantation
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. / Jain, Raksha; Hachem, Ramsey R.; Morrell, Matthew R.; Trulock, Elbert P.; Chakinala, Murali M.; Yusen, Roger D.; Huang, Howard J.; Mohanakumar, Thalachallour; Patterson, G. Alexander; Walter, Michael J.

In: Journal of Heart and Lung Transplantation, Vol. 29, No. 5, 05.2010, p. 531-537.

Research output: Contribution to journalArticle

Jain, R, Hachem, RR, Morrell, MR, Trulock, EP, Chakinala, MM, Yusen, RD, Huang, HJ, Mohanakumar, T, Patterson, GA & Walter, MJ 2010, 'Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome', Journal of Heart and Lung Transplantation, vol. 29, no. 5, pp. 531-537. https://doi.org/10.1016/j.healun.2009.12.003
Jain, Raksha ; Hachem, Ramsey R. ; Morrell, Matthew R. ; Trulock, Elbert P. ; Chakinala, Murali M. ; Yusen, Roger D. ; Huang, Howard J. ; Mohanakumar, Thalachallour ; Patterson, G. Alexander ; Walter, Michael J. / Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. In: Journal of Heart and Lung Transplantation. 2010 ; Vol. 29, No. 5. pp. 531-537.
@article{0ee8c90ab35a432e8dd72a1444abd57f,
title = "Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome",
abstract = "Background: Previous studies have suggested that azithromycin improves lung function in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). However, these studies did not include a non-treated BOS control cohort or perform survival analysis. This study was undertaken to estimate the effect of azithromycin treatment on survival in lung transplant recipients with BOS. Methods: We conducted a retrospective cohort study of consecutive lung transplant recipients who developed BOS between 1999 and 2007. An association between azithromycin treatment and death was assessed using univariate and multivariate time-dependent Cox regression analysis. Results: Of the 178 recipients who developed BOS in our study, 78 did so after 2003 and were treated with azithromycin. The azithromycin-treated and untreated cohorts had similar baseline characteristics. Univariate analysis demonstrated that azithromycin treatment was associated with a survival advantage and this beneficial treatment effect was more pronounced when treatment was initiated during BOS Stage 1. Multivariate analysis demonstrated azithromycin treatment during BOS Stage 1 (adjusted hazard ratio = 0.23, p = 0.01) and absolute forced expiratory volume in 1 second (FEV1) at the time of BOS Stage 1 (adjusted hazard ratio = 0.52, p = 0.003) were both associated with a decreased risk of death. Conclusions: In lung transplant recipients with BOS Stage 1, azithromycin treatment initiated before BOS Stage 2 was independently associated with a significant reduction in the risk of death. This finding supports the need for a randomized, controlled trial to confirm the impact of azithromycin on survival in lung transplant recipients.",
keywords = "azithromycin, bronchiolitis, chronic rejection, lung transplant, macrolides, survival",
author = "Raksha Jain and Hachem, {Ramsey R.} and Morrell, {Matthew R.} and Trulock, {Elbert P.} and Chakinala, {Murali M.} and Yusen, {Roger D.} and Huang, {Howard J.} and Thalachallour Mohanakumar and Patterson, {G. Alexander} and Walter, {Michael J.}",
year = "2010",
month = "5",
doi = "10.1016/j.healun.2009.12.003",
language = "English (US)",
volume = "29",
pages = "531--537",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome

AU - Jain, Raksha

AU - Hachem, Ramsey R.

AU - Morrell, Matthew R.

AU - Trulock, Elbert P.

AU - Chakinala, Murali M.

AU - Yusen, Roger D.

AU - Huang, Howard J.

AU - Mohanakumar, Thalachallour

AU - Patterson, G. Alexander

AU - Walter, Michael J.

PY - 2010/5

Y1 - 2010/5

N2 - Background: Previous studies have suggested that azithromycin improves lung function in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). However, these studies did not include a non-treated BOS control cohort or perform survival analysis. This study was undertaken to estimate the effect of azithromycin treatment on survival in lung transplant recipients with BOS. Methods: We conducted a retrospective cohort study of consecutive lung transplant recipients who developed BOS between 1999 and 2007. An association between azithromycin treatment and death was assessed using univariate and multivariate time-dependent Cox regression analysis. Results: Of the 178 recipients who developed BOS in our study, 78 did so after 2003 and were treated with azithromycin. The azithromycin-treated and untreated cohorts had similar baseline characteristics. Univariate analysis demonstrated that azithromycin treatment was associated with a survival advantage and this beneficial treatment effect was more pronounced when treatment was initiated during BOS Stage 1. Multivariate analysis demonstrated azithromycin treatment during BOS Stage 1 (adjusted hazard ratio = 0.23, p = 0.01) and absolute forced expiratory volume in 1 second (FEV1) at the time of BOS Stage 1 (adjusted hazard ratio = 0.52, p = 0.003) were both associated with a decreased risk of death. Conclusions: In lung transplant recipients with BOS Stage 1, azithromycin treatment initiated before BOS Stage 2 was independently associated with a significant reduction in the risk of death. This finding supports the need for a randomized, controlled trial to confirm the impact of azithromycin on survival in lung transplant recipients.

AB - Background: Previous studies have suggested that azithromycin improves lung function in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). However, these studies did not include a non-treated BOS control cohort or perform survival analysis. This study was undertaken to estimate the effect of azithromycin treatment on survival in lung transplant recipients with BOS. Methods: We conducted a retrospective cohort study of consecutive lung transplant recipients who developed BOS between 1999 and 2007. An association between azithromycin treatment and death was assessed using univariate and multivariate time-dependent Cox regression analysis. Results: Of the 178 recipients who developed BOS in our study, 78 did so after 2003 and were treated with azithromycin. The azithromycin-treated and untreated cohorts had similar baseline characteristics. Univariate analysis demonstrated that azithromycin treatment was associated with a survival advantage and this beneficial treatment effect was more pronounced when treatment was initiated during BOS Stage 1. Multivariate analysis demonstrated azithromycin treatment during BOS Stage 1 (adjusted hazard ratio = 0.23, p = 0.01) and absolute forced expiratory volume in 1 second (FEV1) at the time of BOS Stage 1 (adjusted hazard ratio = 0.52, p = 0.003) were both associated with a decreased risk of death. Conclusions: In lung transplant recipients with BOS Stage 1, azithromycin treatment initiated before BOS Stage 2 was independently associated with a significant reduction in the risk of death. This finding supports the need for a randomized, controlled trial to confirm the impact of azithromycin on survival in lung transplant recipients.

KW - azithromycin

KW - bronchiolitis

KW - chronic rejection

KW - lung transplant

KW - macrolides

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=77950518522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950518522&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2009.12.003

DO - 10.1016/j.healun.2009.12.003

M3 - Article

VL - 29

SP - 531

EP - 537

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 5

ER -